My Bibliography

select

Wormsbaecher C, Cumbia BM, Amurgis EG, Poska JM, Price MR, Mo XM, Knoblaugh SE, Kurita T, Burd CJ. Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice. Endocr Relat Cancer. 2023 Dec 1;30(12). doi: 10.1530/ERC-23-0062. Print 2023 Dec 1. PubMed PMID: 37855322; PubMed Central PMCID: PMC10698735.

select

Bowman RL, Hennessey RC, Weiss TJ, Tallman DA, Crawford ER, Murphy BM, Webb A, Zhang S, La Perle KM, Burd CJ, Levine RL, Shain AH, Burd CE. UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma. Life Sci Alliance. 2021 Sep;4(9). doi: 10.26508/lsa.202101135. Print 2021 Sep. PubMed PMID: 34210801; PubMed Central PMCID: PMC8321651.

select

Haines CN, Klingensmith HD, Komara M, Burd CJ. GREB1 regulates PI3K/Akt signaling to control hormone-sensitive breast cancer proliferation. Carcinogenesis. 2020 Dec 31;41(12):1660-1670. doi: 10.1093/carcin/bgaa096. PubMed PMID: 32894276; PubMed Central PMCID: PMC7791615.

select

Wormsbaecher C, Hindman AR, Avendano A, Cortes-Medina M, Jones CE, Bushman A, Onua L, Kovalchin CE, Murphy AR, Helber HL, Shapiro A, Voytovitch K, Kuang X, Aguilar-Valenzuela R, Leight JL, Song JW, Burd CJ. In utero estrogenic endocrine disruption alters the stroma to increase extracellular matrix density and mammary gland stiffness. Breast Cancer Res. 2020 May 5;22(1):41. doi: 10.1186/s13058-020-01275-w. PubMed PMID: 32370801; PubMed Central PMCID: PMC7201668.

select

Haines CN, Braunreiter KM, Mo XM, Burd CJ. GREB1 isoforms regulate proliferation independent of ERα co-regulator activities in breast cancer. Endocr Relat Cancer. 2018 Jul;25(7):735-746. doi: 10.1530/ERC-17-0496. Epub 2018 Apr 25. PubMed PMID: 29695586; PubMed Central PMCID: PMC7158201.

select

Hindman AR, Mo XM, Helber HL, Kovalchin CE, Ravichandran N, Murphy AR, Fagan AM, St John PM, Burd CJ. Varying Susceptibility of the Female Mammary Gland to In Utero Windows of BPA Exposure. Endocrinology. 2017 Oct 1;158(10):3435-3447. doi: 10.1210/en.2017-00116. PubMed PMID: 28938483; PubMed Central PMCID: PMC5659685.

select

Young NA, Valiente GR, Hampton JM, Wu LC, Burd CJ, Willis WL, Bruss M, Steigelman H, Gotsatsenko M, Amici SA, Severin M, Claverie LM, Guerau-de-Arellano M, Lovett-Racke A, Ardoin S, Jarjour WN. Estrogen-regulated STAT1 activation promotes TLR8 expression to facilitate signaling via microRNA-21 in systemic lupus erythematosus. Clin Immunol. 2017 Mar;176:12-22. doi: 10.1016/j.clim.2016.12.005. Epub 2016 Dec 27. PubMed PMID: 28039018; PubMed Central PMCID: PMC5815376.

select

Lavender CA, Cannady KR, Hoffman JA, Trotter KW, Gilchrist DA, Bennett BD, Burkholder AB, Burd CJ, Fargo DC, Archer TK. Downstream Antisense Transcription Predicts Genomic Features That Define the Specific Chromatin Environment at Mammalian Promoters. PLoS Genet. 2016 Aug;12(8):e1006224. doi: 10.1371/journal.pgen.1006224. eCollection 2016 Aug. PubMed PMID: 27487356; PubMed Central PMCID: PMC4972320.

select

Patterson AR, Mo X, Shapiro A, Wernke KE, Archer TK, Burd CJ. Sustained reprogramming of the estrogen response after chronic exposure to endocrine disruptors. Mol Endocrinol. 2015 Mar;29(3):384-95. doi: 10.1210/me.2014-1237. Epub 2015 Jan 16. PubMed PMID: 25594248; PubMed Central PMCID: PMC4347288.

select

Young NA, Wu LC, Burd CJ, Friedman AK, Kaffenberger BH, Rajaram MV, Schlesinger LS, James H, Shupnik MA, Jarjour WN. Estrogen modulation of endosome-associated toll-like receptor 8: an IFNα-independent mechanism of sex-bias in systemic lupus erythematosus. Clin Immunol. 2014 Mar;151(1):66-77. doi: 10.1016/j.clim.2014.01.006. Epub 2014 Jan 24. PubMed PMID: 24525049; PubMed Central PMCID: PMC4066385.

select

Burd CJ, Archer TK. Chromatin architecture defines the glucocorticoid response. Mol Cell Endocrinol. 2013 Nov 5;380(1-2):25-31. doi: 10.1016/j.mce.2013.03.020. Epub 2013 Mar 29. Review. PubMed PMID: 23545159; PubMed Central PMCID: PMC3762934.

select

Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, Jernigan DL, Dean JL, Fatatis A, McDonnell DP, Visakorpi T, Feng FY, Knudsen KE. Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. J Clin Invest. 2013 Jan;123(1):493-508. doi: 10.1172/JCI64750. Epub 2012 Dec 21. PubMed PMID: 23257359; PubMed Central PMCID: PMC3533295.

select

Burd CJ, Ward JM, Crusselle-Davis VJ, Kissling GE, Phadke D, Shah RR, Archer TK. Analysis of chromatin dynamics during glucocorticoid receptor activation. Mol Cell Biol. 2012 May;32(10):1805-17. doi: 10.1128/MCB.06206-11. Epub 2012 Mar 26. PubMed PMID: 22451486; PubMed Central PMCID: PMC3347412.

select

Comstock CES, Augello MA, Schiewer MJ, Karch J, Burd CJ, Ertel A, Knudsen ES, Jessen WJ, Aronow BJ, Knudsen KE. Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. J Biol Chem. 2011 Mar 11;286(10):8117-8127. doi: 10.1074/jbc.M110.170720. Epub 2011 Jan 5. PubMed PMID: 21212260; PubMed Central PMCID: PMC3048698.

select

Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, Tindall EA, Wang Y, Burd CJ, Groh EM, Hoang HN, Giles GG, Severi G, Hayes VM, Henderson BE, Le Marchand L, Kolonel LN, Haiman CA, Baffa R, Gomella LG, Knudsen ES, Rui H, Henshall SM, Sutherland RL, Knudsen KE. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res. 2009 Sep 1;15(17):5338-49. doi: 10.1158/1078-0432.CCR-08-2865. Epub 2009 Aug 25. PubMed PMID: 19706803; PubMed Central PMCID: PMC2849314.

select

Schiewer MJ, Morey LM, Burd CJ, Liu Y, Merry DE, Ho SM, Knudsen KE. Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer. Oncogene. 2009 Feb 19;28(7):1016-27. doi: 10.1038/onc.2008.446. Epub 2008 Dec 15. PubMed PMID: 19079343; PubMed Central PMCID: PMC2852245.

select

Burd CJ, Kinyamu HK, Miller FW, Archer TK. UV radiation regulates Mi-2 through protein translation and stability. J Biol Chem. 2008 Dec 12;283(50):34976-82. doi: 10.1074/jbc.M805383200. Epub 2008 Oct 15. PubMed PMID: 18922793; PubMed Central PMCID: PMC2596409.

select

Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res. 2008 Jul 15;68(14):5628-38. doi: 10.1158/0008-5472.CAN-07-3170. PubMed PMID: 18632615; PubMed Central PMCID: PMC8220573.

select

Olshavsky NA, Groh EM, Comstock CE, Morey LM, Wang Y, Revelo MP, Burd C, Meller J, Knudsen KE. Cyclin D3 action in androgen receptor regulation and prostate cancer. Oncogene. 2008 May 15;27(22):3111-21. doi: 10.1038/sj.onc.1210981. Epub 2007 Dec 17. PubMed PMID: 18084330.

select

Burd CJ, Morey LM, Knudsen KE. Androgen receptor corepressors and prostate cancer. Endocr Relat Cancer. 2006 Dec;13(4):979-94. doi: 10.1677/erc.1.01115. Review. PubMed PMID: 17158750.

select

Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, Haiman CA, Lu S, Fenoglio-Preiser CM, Li J, Knudsen ES, Wong J, Knudsen KE. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2190-5. doi: 10.1073/pnas.0506281103. Epub 2006 Feb 6. PubMed PMID: 16461912; PubMed Central PMCID: PMC1413684.

select

Link KA, Burd CJ, Williams E, Marshall T, Rosson G, Henry E, Weissman B, Knudsen KE. BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF. Mol Cell Biol. 2005 Mar;25(6):2200-15. doi: 10.1128/MCB.25.6.2200-2215.2005. PubMed PMID: 15743818; PubMed Central PMCID: PMC1061596.

select

Burd CJ, Petre CE, Moghadam H, Wilson EM, Knudsen KE. Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. Mol Endocrinol. 2005 Mar;19(3):607-20. doi: 10.1210/me.2004-0266. Epub 2004 Nov 11. PubMed PMID: 15539430.

select

Petre-Draviam CE, Williams EB, Burd CJ, Gladden A, Moghadam H, Meller J, Diehl JA, Knudsen KE. A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene. 2005 Jan 13;24(3):431-44. doi: 10.1038/sj.onc.1208200. PubMed PMID: 15558026.

select

Petre-Draviam CE, Cook SL, Burd CJ, Marshall TW, Wetherill YB, Knudsen KE. Specificity of cyclin D1 for androgen receptor regulation. Cancer Res. 2003 Aug 15;63(16):4903-13. PubMed PMID: 12941814.

select

Liby K, Neltner B, Mohamet L, Burd C, Ben-Jonathan N. Endostatin expression by MDA-MB-435 breast cancer cells effectively inhibits tumor growth. Cancer Biol Ther. 2003 Jan-Feb;2(1):48-52. doi: 10.4161/cbt.179. PubMed PMID: 12673115.

select

Singleton DW, Feng Y, Burd CJ, Khan SA. Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells. Endocrinology. 2003 Jan;144(1):121-8. doi: 10.1210/en.2002-220625. PubMed PMID: 12488337.

select

Farr CD, Burd C, Tabet MR, Wang X, Welsh WJ, Ball WJ Jr. Three-dimensional quantitative structure-activity relationship study of the inhibition of Na(+),K(+)-ATPase by cardiotonic steroids using comparative molecular field analysis. Biochemistry. 2002 Jan 29;41(4):1137-48. doi: 10.1021/bi011511g. PubMed PMID: 11802712.

select

Burd CJ, Dobson AJ, Gerkin RE. Alpha and beta phases of 4-aminoquinoline-2-carboxylic acid monohydrate. Acta Crystallogr C. 1997 May 15;53 ( Pt 5):602-5. doi: 10.1107/s0108270197000565. PubMed PMID: 9176989.

select

Burd CJ, Dobson AJ, Gerkin RE. Redetermination of octahydrochrysene. Acta Crystallogr C. 1996 May 15;52 ( Pt 5):1241-3. doi: 10.1107/s0108270195015460. PubMed PMID: 8652097.